Exact Sciences Q1 top line up 227%; net loss narrows 27%; number of Cologuard tests performed up 150%; shares ahead 21% premarket

|By:, SA News Editor

Exact Sciences (NASDAQ:EXAS) Q1 results ($M): Revenue: 48.4 (+227.0%).

Net Loss: (34.9) (+26.5%); Loss/Share: (0.32) (+34.7%).

Cologuard tests performed: ~100K (+150.0%). Average cost/test: $170 (-25.1%).

2017 Guidance: Revenue: $195M - 205M from $170M - 180M; Cologuard tests performed: at least 470K from at least 415K.

Q2 Guidance: At least 115K Cologuard tests performed.

Shares are up 21% premarket on light volume.